Literature DB >> 22193844

The effect of iron overload and chelation on erythroid differentiation.

Kazuki Taoka1, Keiki Kumano, Fumihiko Nakamura, Masataka Hosoi, Susumu Goyama, Yoichi Imai, Akira Hangaishi, Mineo Kurokawa.   

Abstract

We investigated the mechanisms of hematopoietic disorders caused by iron overload and chelation, in particular, the inhibition of erythroblast differentiation. Murine c-kit(+) progenitor cells or human CD34(+) peripheral blood hematopoietic progenitors were differentiated in vitro to the erythroid lineage with free iron and/or an iron chelator. Under iron overload, formation of erythroid burst-forming unit colonies and differentiation to mature erythroblasts were significantly suppressed; these effects were canceled by iron chelation with deferoxamine (DFO). Moreover, excessive iron burden promoted apoptosis in immature erythroblasts by elevating intracellular reactive oxygen species (ROS). Interestingly, both DFO and a potent anti-oxidant agent reduced intracellular ROS levels and suppressed apoptosis, thus restoring differentiation to mature erythroblasts. Accordingly, intracellular ROS may represent a new therapeutic target in the treatment of iron overload.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193844     DOI: 10.1007/s12185-011-0988-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  35 in total

1.  Semi-quantitative estimation of heme/hemoprotein with dichlorodihydrofluorescin diacetate.

Authors:  Tomoko Ohashi; Kazuhiro Kakimoto; Yoshihiro Sokawa; Shigeru Taketani
Journal:  Anal Biochem       Date:  2002-09-15       Impact factor: 3.365

Review 2.  Life-or-death decisions by the Bcl-2 protein family.

Authors:  J M Adams; S Cory
Journal:  Trends Biochem Sci       Date:  2001-01       Impact factor: 13.807

3.  Rapid oxidation of dichlorodihydrofluorescin with heme and hemoproteins: formation of the fluorescein is independent of the generation of reactive oxygen species.

Authors:  Tomoko Ohashi; Atsushi Mizutani; Akira Murakami; Shosuke Kojo; Tetsuro Ishii; Shigeru Taketani
Journal:  FEBS Lett       Date:  2002-01-30       Impact factor: 4.124

4.  Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death.

Authors:  A Atlante; P Calissano; A Bobba; A Azzariti; E Marra; S Passarella
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

5.  Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?

Authors:  A Cortelezzi; C Cattaneo; S Cristiani; L Duca; B Sarina; G L Deliliers; G Fiorelli; M D Cappellini
Journal:  Hematol J       Date:  2000

6.  Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

Authors:  E Messa; D Cilloni; F Messa; F Arruga; A Roetto; G Saglio
Journal:  Acta Haematol       Date:  2008-10-01       Impact factor: 2.195

Review 7.  Cellular defenses against superoxide and hydrogen peroxide.

Authors:  James A Imlay
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

8.  Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

Authors:  F N al-Refaie; D G Wickens; B Wonke; G J Kontoghiorghes; A V Hoffbrand
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

9.  Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

Authors:  Anna Angela Di Tucci; Roberta Murru; Daniele Alberti; Bertrand Rabault; Simona Deplano; Emanuele Angelucci
Journal:  Eur J Haematol       Date:  2007-03-28       Impact factor: 2.997

Review 10.  Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.

Authors:  J F Kerr; A H Wyllie; A R Currie
Journal:  Br J Cancer       Date:  1972-08       Impact factor: 7.640

View more
  19 in total

1.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 2.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

3.  Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.

Authors:  G Visani; B Guiducci; C Giardini; F Loscocco; T Ricciardi; A Isidori
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

4.  Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.

Authors:  Hiroshi Kawabata; Kensuke Usuki; Maki Shindo-Ueda; Junya Kanda; Kaoru Tohyama; Akira Matsuda; Kayano Araseki; Tomoko Hata; Takahiro Suzuki; Hidekazu Kayano; Kei Shimbo; Shigeru Chiba; Takayuki Ishikawa; Nobuyoshi Arima; Masaharu Nohgawa; Yasushi Miyazaki; Mineo Kurokawa; Shunya Arai; Kinuko Mitani; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2019-07-29       Impact factor: 2.490

Review 5.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

Review 6.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.

Authors:  Minoru Kojima; Shinichiro Machida; Ai Sato; Mitsuki Miyamoto; Makiko Moriuchi; Yoshiaki Ohbayashi; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2013-10-26       Impact factor: 2.490

8.  Deposition of Iron in the Bone Marrow of a Murine Model of Hematopoietic Acute Radiation Syndrome.

Authors:  W Bradley Rittase; Jeannie M Muir; John E Slaven; Roxane M Bouten; Michelle A Bylicky; W Louis Wilkins; Regina M Day
Journal:  Exp Hematol       Date:  2020-03-30       Impact factor: 3.084

9.  Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.

Authors:  Mariko Noguchi-Sasaki; Yusuke Sasaki; Yukari Matsuo-Tezuka; Hideyuki Yasuno; Mitsue Kurasawa; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2016-01-06       Impact factor: 2.490

Review 10.  Physiology and pathophysiology of iron in hemoglobin-associated diseases.

Authors:  Thomas D Coates
Journal:  Free Radic Biol Med       Date:  2014-04-12       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.